Health
China’s Sinovac reports mixed findings in early coronavirus vaccine trials – The Washington Post
Study found the vaccine candidate produced a quick immune response but lower levels of antibodies than in recovered coronavirus patients.
These early results put Sinovac on the back foot to prove its vaccine is effective in ongoing Phase 3 trials.
That is a concern, said Thomas Campbell, associate dean for clinical research at the University of Colorado, of the low antibody levels in Sinovacs Phase 2 trial. Its an important point here, in terms of comparing this vaccine to, for instance, the Moderna and Pfizer vaccines.
As the world awaits a coronavirus vaccine, some in China get early doses
Indonesia, the worlds fourth-most populous…
-
Noosa News24 hours agoTerrifying break-in at childcare centre on Sunshine Coast ends with death of man
-
Noosa News21 hours agoADF to introduce billion-dollar drone dome over Brisbane 2032
-
General19 hours agoQueensland government strikes new deal with Bravus to defer royalties, expand Carmichael coal mine
-
Noosa News22 hours agoRosemarie Campbell’s post-surgery deterioration score miscalculated at The Wesley Hospital, inquest into her death hears